[News Release & Highlights](index=1&type=section&id=News%20Release) [CEO Statement](index=1&type=section&id=CEO%20Statement) Robert B. Ford, Chairman and CEO, highlighted consistent, high-quality performance in Q3 2025, attributing it to a differentiated product pipeline that positions Abbott for durable long-term value to shareholders - Robert B. Ford, chairman and chief executive officer, Abbott, stated: 'Our third-quarter results demonstrate our ability to deliver **consistent, high-quality performance**. Our differentiated product pipeline continues to power our performance and positions Abbott to deliver **durable long-term value** to our shareholders'[2](index=2&type=chunk) [Key Financial Highlights (3Q25 & YTD)](index=1&type=section&id=Key%20Financial%20Highlights) Abbott reported strong financial results for Q3 2025, with significant sales growth and adjusted diluted EPS, alongside positive year-to-date performance, demonstrating consistent execution Key Financial Highlights (3Q25 & YTD) | Metric | 3Q25 Reported | 3Q25 Organic (excl. COVID-19) | YTD Reported | YTD Organic (excl. COVID-19) | | :----- | :------------ | :---------------------------- | :----------- | :--------------------------- | | Sales Growth | 6.9% | 7.5% | 6.1% | 7.7% | | GAAP Diluted EPS | $0.94 | N/A | N/A | N/A | | Adjusted Diluted EPS | $1.30 | N/A | N/A | N/A | | Reported Operating Margin | 18.1% | N/A | N/A | N/A | | Adjusted Operating Margin | 23.0% (40 bps increase) | N/A | N/A | N/A | [Recent Product & Regulatory Milestones](index=1&type=section&id=Recent%20Product%20%26%20Regulatory%20Milestones) Abbott achieved key regulatory approvals and received supportive treatment guidelines for its innovative medical devices, enhancing its market position in cardiovascular health - Regulatory approval in Japan for TriClip®, a first-of-its-kind, minimally invasive treatment option for patients with tricuspid regurgitation[2](index=2&type=chunk) - CE Mark received for an expanded indication for the Navitor® transcatheter aortic valve implantation (TAVI) system to treat symptomatic, severe aortic stenosis patients at low or intermediate risk for open-heart surgery[2](index=2&type=chunk) - New treatment guidelines issued at the European Society of Cardiology (ESC) Congress provide additional support for the use of MitraClip® and TriClip® in treating valvular heart disease[2](index=2&type=chunk) [Third-Quarter Business Overview](index=2&type=section&id=THIRD-QUARTER%20BUSINESS%20OVERVIEW) [Overall Sales Performance (3Q25 & 9M25)](index=2&type=section&id=Overall%20Sales%20Performance) Abbott's overall sales demonstrated solid growth in Q3 and year-to-date 2025, particularly when excluding the declining impact of COVID-19 testing sales, with organic growth being a key metric for performance assessment - Management measures sales growth rates on an organic basis, excluding foreign exchange impact and the discontinuation of the ZonePerfect® product line, to understand core underlying business performance[3](index=3&type=chunk) Total Company Sales (3Q25 vs 3Q24) | Metric | Total Company | Nutrition | Diagnostics | Established Pharmaceuticals | Medical Devices | | :----- | :------------ | :-------- | :---------- | :------------------------ | :-------------- | | Total reported sales ($M) | 11,369 | 2,153 | 2,253 | 1,511 | 5,448 | | Total reported % Change | 6.9% | 4.2% | (6.6)% | 7.5% | 14.8% | | Organic % Change | 5.5% | 4.0% | (7.8)% | 7.1% | 12.5% | | Organic (excl. COVID-19 tests) % Change | 7.5% | 4.0% | 0.4% | 7.1% | 12.5% | Total Company Sales (9M25 vs 9M24) | Metric | Total Company | Nutrition | Diagnostics | Established Pharmaceuticals | Medical Devices | | :----- | :------------ | :-------- | :---------- | :------------------------ | :-------------- | | Total reported sales ($M) | 32,869 | 6,511 | 6,480 | 4,154 | 15,712 | | Total reported % Change | 6.1% | 3.6% | (5.0)% | 5.8% | 12.8% | | Organic % Change | 6.4% | 4.7% | (4.8)% | 7.5% | 12.4% | | Organic (excl. COVID-19 tests) % Change | 7.7% | 4.7% | 0.6% | 7.5% | 12.4% | [Nutrition Segment Performance](index=3&type=section&id=Nutrition) The Nutrition segment achieved reported sales growth of 4.2% and organic growth of 4.0% in Q3 2025, primarily driven by strong performance in Adult Nutrition, particularly from Ensure® and Glucerna® brands Nutrition Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Pediatric | Adult | | :------------------------ | :---- | :-------- | :---- | | U.S. | 888 | 520 | 368 | | International | 1,265 | 457 | 808 | | Total reported | 2,153 | 977 | 1,176 | | % Change vs. 3Q24 | | | | | U.S. | (6.5) | (8.4) | (3.8) | | International | 13.3 | 17.9 | 10.9 | | Total reported | 4.2 | 2.3 | 5.8 | | Impact of foreign exchange | 0.2 | (0.1) | 0.4 | | Organic | 4.0 | 2.4 | 5.4 | - Growth in the quarter was led by Adult Nutrition, with sales increasing **5.8 percent reported** and **5.4 percent organic**, driven by strong growth of Ensure® and Glucerna®[9](index=9&type=chunk) Nutrition Sales (9M25 vs 9M24) | Sales 9M25 ($ in millions) | Total | Pediatric | Adult | | :------------------------ | :---- | :-------- | :---- | | U.S. | 2,800 | 1,695 | 1,105 | | International | 3,711 | 1,377 | 2,334 | | Total reported | 6,511 | 3,072 | 3,439 | | % Change vs. 9M24 | | | | | U.S. | 1.4 | 3.0 | (0.9) | | International | 5.3 | — | 8.8 | | Total reported | 3.6 | 1.6 | 5.5 | | Impact of foreign exchange | (0.9) | (0.9) | (0.9) | | Impact of business exit* | (0.2) | — | (0.4) | | Organic | 4.7 | 2.5 | 6.8 | [Diagnostics Segment Performance](index=4&type=section&id=Diagnostics) Global Diagnostics sales decreased in Q3 2025 on a reported and organic basis, primarily due to a significant decline in COVID-19 testing-related sales. Excluding COVID-19 tests, organic sales showed slight growth, with Core Laboratory Diagnostics experiencing growth despite challenging market conditions in China Diagnostics Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Core Laboratory | Molecular | Point of Care | Rapid Diagnostics | | :------------------------ | :---- | :-------------- | :-------- | :------------ | :---------------- | | U.S. | 886 | 366 | 36 | 111 | 373 | | International | 1,367 | 998 | 95 | 47 | 227 | | Total reported | 2,253 | 1,364 | 131 | 158 | 600 | | % Change vs. 3Q24 | | | | | | | U.S. | (14.1) | 10.4 | (1.5) | 7.9 | (33.5) | | International | (1.0) | 1.6 | 4.3 | 8.9 | (14.2) | | Total reported | (6.6) | 3.8 | 2.6 | 8.2 | (27.3) | | Impact of foreign exchange | 1.2 | 1.6 | 1.8 | 0.4 | 0.4 | | Organic | (7.8) | 2.2 | 0.8 | 7.8 | (27.7) | | Organic (excluding COVID-19 tests) | 0.4 | N/A | N/A | N/A | N/A | - COVID-19 testing-related sales were **$69 million** in Q3 2025, a significant decrease from **$265 million** in Q3 2024[10](index=10&type=chunk) - Core Laboratory Diagnostics sales increased **3.8 percent reported** and **2.2 percent organic**, despite challenging market conditions in China, including volume-based procurement programs[11](index=11&type=chunk) [Established Pharmaceuticals Segment Performance](index=5&type=section&id=Established%20Pharmaceuticals) Established Pharmaceuticals sales increased 7.5% on a reported basis and 7.1% organically in Q3 2025, primarily driven by double-digit organic growth in Key Emerging Markets across Asia, Latin America, and the Middle East Established Pharmaceuticals Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Key Emerging Markets | Other | | :------------------------ | :---- | :------------------- | :---- | | International | 1,511 | 1,097 | 414 | | Total reported | 1,511 | 1,097 | 414 | | % Change vs. 3Q24 | | | | | International | 7.5 | 10.3 | 0.6 | | Total reported | 7.5 | 10.3 | 0.6 | | Impact of foreign exchange | 0.4 | (0.8) | 3.1 | | Organic | 7.1 | 11.1 | (2.5) | - Sales in Key Emerging Markets increased **10.3 percent reported** and **11.1 percent organic**, driven by double-digit growth in several countries across Asia, Latin America, and the Middle East[14](index=14&type=chunk) Established Pharmaceuticals Sales (9M25 vs 9M24) | Sales 9M25 ($ in millions) | Total | Key Emerging Markets | Other | | :------------------------ | :---- | :------------------- | :---- | | International | 4,154 | 3,121 | 1,033 | | Total reported | 4,154 | 3,121 | 1,033 | | % Change vs. 9M24 | | | | | International | 5.8 | 7.3 | 1.7 | | Total reported | 5.8 | 7.3 | 1.7 | | Impact of foreign exchange | (1.7) | (2.4) | 0.5 | | Organic | 7.5 | 9.7 | 1.2 | [Medical Devices Segment Performance](index=6&type=section&id=Medical%20Devices) The Medical Devices segment delivered strong performance in Q3 2025, with reported sales increasing 14.8% and organic sales growing 12.5%, driven by double-digit growth across several key areas including Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure, and Structural Heart Medical Devices Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Rhythm Management | Electrophysiology | Heart Failure | Vascular | Structural Heart | Neuromodulation | Diabetes Care | | :------------------------ | :---- | :---------------- | :---------------- | :------------ | :------- | :--------------- | :-------------- | :------------ | | U.S. | 2,521 | 350 | 322 | 280 | 280 | 297 | 196 | 796 | | International | 2,927 | 336 | 383 | 86 | 465 | 338 | 58 | 1,261 | | Total reported | 5,448 | 686 | 705 | 366 | 745 | 635 | 254 | 2,057 | | % Change vs. 3Q24 | | | | | | | | | | U.S. | 13.8 | 21.1 | 13.2 | 10.7 | 8.5 | 10.1 | 3.3 | 18.4 | | International | 15.6 | 9.3 | 17.6 | 22.6 | 5.5 | 16.9 | 24.9 | 19.9 | | Total reported | 14.8 | 15.0 | 15.6 | 13.3 | 6.6 | 13.6 | 7.6 | 19.3 | | Impact of foreign exchange | 2.3 | 2.0 | 1.9 | 1.2 | 1.9 | 2.3 | 0.8 | 3.1 | | Organic | 12.5 | 13.0 | 13.7 | 12.1 | 4.7 | 11.3 | 6.8 | 16.2 | - Sales growth in Q3 was led by **double-digit growth** in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure, and Structural Heart[17](index=17&type=chunk) - Diabetes Care sales of continuous glucose monitors reached **$2.0 billion**, growing **20.5 percent reported** and **17.2 percent organic**[17](index=17&type=chunk) [Abbott's Financial Guidance & Shareholder Information](index=7&type=section&id=ABBOTT%27S%20FINANCIAL%20GUIDANCE) [Full-Year 2025 Financial Guidance](index=7&type=section&id=Full-Year%202025%20Financial%20Guidance) Abbott reaffirmed its full-year 2025 organic sales growth guidance and narrowed its adjusted diluted EPS guidance range, reflecting anticipated double-digit growth - Abbott reaffirms full-year 2025 organic sales growth guidance of **7.5% to 8.0%** (excluding COVID-19 testing-related sales) or **6.0% to 7.0%** (including COVID-19 testing-related sales)[19](index=19&type=chunk) - Abbott reaffirms the midpoint of full-year 2025 adjusted diluted EPS guidance and narrows the range to **$5.12 to $5.18**, reflecting **double-digit growth** at the midpoint[19](index=19&type=chunk) [Dividend Declaration](index=7&type=section&id=ABBOTT%20DECLARES%20407%20CONSECUTIVE%20QUARTERLY%20DIVIDEND) Abbott declared its 407th consecutive quarterly dividend of $0.59 per share, payable in November 2025, underscoring its long-standing commitment to shareholder returns as a Dividend Aristocrat - On Sept. 19, 2025, Abbott's board of directors declared a quarterly dividend of **$0.59 per share**[21](index=21&type=chunk) - The cash dividend is payable Nov. 17, 2025, to shareholders of record on Oct. 15, 2025[21](index=21&type=chunk) - Abbott has increased its dividend payout for **53 consecutive years** and is a member of the S&P 500 Dividend Aristocrats Index[21](index=21&type=chunk) [Company Overview](index=7&type=section&id=About%20Abbott%3A) Abbott is a global healthcare leader providing life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries with 114,000 employees - Abbott is a global healthcare leader with a portfolio of life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines[22](index=22&type=chunk) - The company has **114,000 colleagues** serving people in more than **160 countries**[22](index=22&type=chunk) [Financial Statements & Non-GAAP Reconciliations](index=9&type=section&id=Abbott%20Laboratories%20and%20Subsidiaries) [Condensed Consolidated Statement of Earnings](index=9&type=section&id=Condensed%20Consolidated%20Statement%20of%20Earnings) The condensed consolidated statements of earnings for Q3 and 9M 2025 show net sales growth and changes in operating earnings, net earnings, and diluted EPS compared to the prior year, both on a GAAP and adjusted basis Condensed Consolidated Statement of Earnings (3Q25 vs 3Q24) | Metric | 3Q25 ($M) | 3Q24 ($M) | % Change | | :----- | :-------- | :-------- | :------- | | Net Sales | $11,369 | $10,635 | 6.9% | | Operating Earnings | $2,057 | $1,859 | 10.6% | | Net Earnings (GAAP) | $1,644 | $1,646 | (0.1)% | | Net Earnings (excl. Specified Items) | $2,278 | $2,119 | 7.5% | | Diluted EPS (GAAP) | $0.94 | $0.94 | — | | Diluted EPS (excl. Specified Items) | $1.30 | $1.21 | 7.4% | Condensed Consolidated Statement of Earnings (9M25 vs 9M24) | Metric | 9M25 ($M) | 9M24 ($M) | % Change | | :----- | :-------- | :-------- | :------- | | Net Sales | $32,869 | $30,976 | 6.1% | | Operating Earnings | $5,802 | $4,914 | 18.1% | | Net Earnings (GAAP) | $4,748 | $4,173 | 13.8% | | Net Earnings (excl. Specified Items) | $6,410 | $5,851 | 9.6% | | Diluted EPS (GAAP) | $2.70 | $2.38 | 13.4% | | Diluted EPS (excl. Specified Items) | $3.65 | $3.33 | 9.6% | [Non-GAAP Financial Information Reconciliation](index=13&type=section&id=Non-GAAP%20Reconciliation%20of%20Financial%20Information) Abbott provides detailed reconciliations from GAAP to adjusted financial measures for Q3 and 9M 2025 and 2024, primarily adjusting for intangible amortization, restructuring, acquisition-related expenses, and other specified items to present a clearer view of core operational performance Non-GAAP Reconciliation (3Q25) | Metric | As Reported (GAAP) ($M) | Specified Items ($M) | As Adjusted ($M) | | :----- | :---------------------- | :------------------- | :--------------- | | Intangible Amortization | $420 | $(420) | $0 | | Gross Margin | $5,874 | $470 | $6,344 | | R&D | $766 | $(36) | $730 | | SG&A | $3,051 | $(47) | $3,004 | | Other (income) expense, net | $(150) | $5 | $(145) | | Earnings before taxes | $2,180 | $548 | $2,728 | | Taxes on Earnings | $536 | $(86) | $450 | | Net Earnings | $1,644 | $634 | $2,278 | | Diluted Earnings per Share | $0.94 | $0.36 | $1.30 | Non-GAAP Reconciliation (3Q24) | Metric | As Reported (GAAP) ($M) | Specified Items ($M) | As Adjusted ($M) | | :----- | :---------------------- | :------------------- | :--------------- | | Intangible Amortization | $470 | $(470) | $0 | | Gross Margin | $5,467 | $516 | $5,983 | | R&D | $713 | $(19) | $694 | | SG&A | $2,895 | $(5) | $2,890 | | Other (income) expense, net | $(121) | $(12) | $(133) | | Earnings before taxes | $1,940 | $552 | $2,492 | | Taxes on Earnings | $294 | $79 | $373 | | Net Earnings | $1,646 | $473 | $2,119 | | Diluted Earnings per Share | $0.94 | $0.27 | $1.21 | Non-GAAP Reconciliation (9M25) | Metric | As Reported (GAAP) ($M) | Specified Items ($M) | As Adjusted ($M) | | :----- | :---------------------- | :------------------- | :--------------- | | Intangible Amortization | $1,260 | $(1,260) | $0 | | Gross Margin | $17,212 | $1,396 | $18,608 | | R&D | $2,207 | $(83) | $2,124 | | SG&A | $9,203 | $(58) | $9,145 | | Other (income) expense, net | $(414) | $(31) | $(445) | | Earnings before taxes | $6,108 | $1,568 | $7,676 | | Taxes on Earnings | $1,360 | $(94) | $1,266 | | Net Earnings | $4,748 | $1,662 | $6,410 | | Diluted Earnings per Share | $2.70 | $0.95 | $3.65 | [Tax Rate Reconciliation](index=15&type=section&id=Tax%20Rate%20Reconciliation) Abbott reconciled its GAAP tax rates to adjusted tax rates for Q3 and 9M 2025 and 2024, showing the impact of specified items and certain tax adjustments on the effective tax rate Tax Rate Reconciliation (3Q25 vs 3Q24) | Metric | 3Q25 GAAP Tax Rate | 3Q25 Adjusted Tax Rate | 3Q24 GAAP Tax Rate | 3Q24 Adjusted Tax Rate | | :----- | :----------------- | :--------------------- | :----------------- | :--------------------- | | Tax Rate | 24.6% | 16.5% | 15.2% | 15.0% | Tax Rate Reconciliation (9M25 vs 9M24) | Metric | 9M25 GAAP Tax Rate | 9M25 Adjusted Tax Rate | 9M24 GAAP Tax Rate | 9M24 Adjusted Tax Rate | | :----- | :----------------- | :--------------------- | :----------------- | :--------------------- | | Tax Rate | 22.3% | 16.5% | 16.3% | 15.0% | [Non-GAAP Revenue Reconciliation](index=16&type=section&id=Non-GAAP%20Revenue%20Reconciliation) Abbott provided a non-GAAP revenue reconciliation for the nine months ended September 30, 2025 and 2024, detailing the impact of discontinuing the ZonePerfect® product line in the Nutrition business on reported and adjusted revenue figures Non-GAAP Revenue Reconciliation (9M25 vs 9M24) | Metric | 9M25 Abbott Reported ($M) | 9M24 Abbott Reported ($M) | Impact from business exit (a) ($M) | 9M24 Adjusted Revenue ($M) | % Change vs. 9M24 Reported | % Change vs. 9M24 Adjusted | Organic % Change | | :----- | :------------------------ | :------------------------ | :--------------------------------- | :------------------------- | :------------------------- | :------------------------- | :--------------- | | Total Company | 32,869 | 30,976 | (13) | 30,963 | 6.1% | 6.1% | 6.4% | | Total Nutrition | 6,511 | 6,284 | (13) | 6,271 | 3.6% | 3.8% | 4.7% | | Adult Nutrition | 3,439 | 3,261 | (13) | 3,248 | 5.5% | 5.9% | 6.8% | - The business exit impact reflects the discontinuation of the ZonePerfect® product line in the Nutrition business, initiated in March 2024[47](index=47&type=chunk) [Details of Specified Items](index=17&type=section&id=Details%20of%20Specified%20Items) This section provides a detailed breakdown of the specific items that are excluded from GAAP financial measures to arrive at adjusted (non-GAAP) figures for the third quarter and nine months ended September 30, 2025 and 2024. These items primarily include intangible amortization, restructuring and cost reduction initiatives, acquisition/divestiture-related expenses, and other adjustments - For 3Q25, specified items include **$420 million** for intangible amortization and **$128 million** for restructuring, acquisition costs, and other net expenses[38](index=38&type=chunk)[49](index=49&type=chunk) - For 3Q24, specified items include **$470 million** for intangible amortization and **$82 million** for intangible impairment, acquisitions, a divestiture, and other net expenses[39](index=39&type=chunk)[52](index=52&type=chunk) - For 9M25, specified items include **$1.260 billion** for intangible amortization and **$308 million** for restructuring, acquisitions, investment impairment charges, and other net expenses[42](index=42&type=chunk)[55](index=55&type=chunk) - For 9M24, specified items include **$1.413 billion** for intangible amortization and **$487 million** for restructuring, acquisitions, a divestiture, and other net expenses[43](index=43&type=chunk)[58](index=58&type=chunk)

Earnings Overview - The third quarter earnings season has commenced with major Wall Street banks reporting results, with analysts expecting a 7.9% increase in earnings per share for S&P 500 companies, marking the ninth consecutive quarter of positive growth but a slowdown from 12% in Q2 [1][28] - Major financial institutions including JPMorgan Chase, Goldman Sachs, Wells Fargo, Citigroup, and BlackRock are among the first to report their earnings [2][3] Company-Specific Highlights - Morgan Stanley reported a 45% surge in profits, driven by a 44% increase in dealmaking fees to $2.1 billion and a 24% rise in trading fees, totaling $6.28 billion [4][6][7] - Abbott's shares fell 1% after reporting diluted earnings per share of $0.94, below the expected $1.04, with revenue of $11.3 billion aligning with estimates [8][9] - Citigroup's net income rose to $3.8 billion, or $1.86 per diluted share, on revenue of $22.1 billion, reflecting a 9% increase in total revenue [13][14] - Johnson & Johnson announced plans to spin off its orthopedics unit while reporting adjusted earnings per share of $2.80, exceeding estimates of $2.76, and raised its 2025 sales forecast by approximately $300 million [18][19][20] - Domino's Pizza saw a nearly 5% increase in stock after reporting a 5.2% acceleration in US same-store sales, with earnings per share of $4.08 surpassing estimates [15][16] Market Trends - The earnings season is characterized by a boom in dealmaking and trading, significantly benefiting banks like Morgan Stanley and Citigroup [10][13] - ASML reported orders exceeding estimates due to an AI investment boom, although it warned of a significant drop in Chinese demand next year [12] - LVMH experienced a surprising return to sales growth, with shares rising as much as 14%, indicating a potential easing in luxury demand decline [11]

Core Insights - Abbott's third-quarter results for 2025 show a total worldwide sales increase of 6.9% to $11.369 billion compared to $10.635 billion in the same quarter of 2024 [23] - The company reported a GAAP diluted EPS of $0.94 and an adjusted diluted EPS of $1.30, reflecting a 7.4% increase from the previous year [7][24] - Abbott reaffirms its full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales [17] Financial Performance - Total reported sales for the third quarter were $11.369 billion, with U.S. sales at $4.299 billion and international sales at $7.070 billion [4] - The organic sales growth was 5.5%, or 7.5% when excluding COVID-19 testing-related sales [7] - Year-to-date sales for the first nine months of 2025 reached $32.869 billion, a 6.1% increase from $30.976 billion in the same period of 2024 [24] Segment Performance - Nutrition segment sales for Q3 2025 were $2.153 billion, with U.S. sales declining by 6.5% and international sales increasing by 13.3% [6][9] - Diagnostics segment reported sales decreased by 6.6% to $2.253 billion, with a notable decline in COVID-19 testing sales from $265 million in Q3 2024 to $69 million in Q3 2025 [10][11] - Medical Devices segment sales increased by 14.8% to $5.448 billion, driven by strong growth in Diabetes Care and other areas [15][16] Guidance and Future Outlook - Abbott has narrowed its full-year 2025 adjusted diluted EPS guidance range to $5.12 to $5.18, indicating double-digit growth at the midpoint [7][17] - The company received regulatory approvals for new products, including TriClip and an expanded indication for the Navitor TAVI system, which are expected to contribute to future growth [7] Dividend Information - Abbott declared a quarterly dividend of $0.59 per share, marking the 407th consecutive quarterly dividend, with a history of increasing dividends for 53 consecutive years [19]

Market Overview - U.S. stock futures advanced on Wednesday following a mixed close on Tuesday, with major benchmark indices showing positive movement [1] - The futures market reacted positively to comments from Federal Reserve Chair Jerome Powell regarding potential rate cuts due to rising downside risks to employment [2] - The 10-year Treasury bond yielded 4.01%, while the two-year bond was at 3.47%, with a 95.7% likelihood of interest rate cuts projected for the October meeting [2] Stock Performance - Major indices showed the following changes: Dow Jones up 0.41%, S&P 500 up 0.54%, Nasdaq 100 up 0.74%, and Russell 2000 up 0.92% [3] - The SPDR S&P 500 ETF Trust (SPY) rose 0.63% to $666.40, and the Invesco QQQ Trust ETF (QQQ) advanced 0.85% to $603.07 in premarket trading [3] Earnings Reports - Bank of America Corp. (BAC) rose 0.76% ahead of earnings, with estimates of $0.95 per share on revenue of $27.50 billion [5] - Morgan Stanley (MS) advanced 1.52%, with earnings estimates of $2.10 per share on revenue of $16.70 billion [5] - Abbott Laboratories (ABT) was up 0.36%, with earnings estimates of $1.30 per share on revenue of $11.40 billion [5] Notable Stocks - ASML Holding NV (ASML) jumped 3.74% after reporting third-quarter net bookings of €5.4 billion ($6.27 billion), indicating a strong price trend [12] - Papa John's International Inc. (PZZA) shares surged 11.69% following a new takeover bid from Apollo Global Management at $64 per share [12] Sector Performance - Industrials, consumer staples, and financials recorded the biggest gains on Tuesday, while consumer discretionary and information technology sectors closed lower [7]

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Bank of America Corp. (NYSE:BAC) to report quarterly earnings at 95 cents per share on revenue of $27.50 billion before the opening bell, according to data from Benzinga Pro. Bank of America shares gained 0.3% to $50.22 in after-hours trading.Papa John's International Inc. (NASDAQ:PZZA) shares rose sharply in extended trading on Tuesday following reports ...

Core Insights - Abbott Laboratories (NYSE:ABT) is recognized as a reliable healthcare company, with positive remarks from Jim Cramer, who described the stock as "terrific" and noted the company's long-standing presence in his investment trust [1] Financial Performance - Abbott Labs reported mixed results in their latest earnings update, which was perceived as disappointing in an otherwise positive market [1] - The company tightened its full-year earnings guidance instead of raising it, indicating a cautious outlook [1] - Abbott also lowered its organic sales growth forecast and operating margin outlook, suggesting potential challenges ahead [1]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Viewpoint - Synlait Milk Limited, a subsidiary of Bright Dairy, plans to sell its North Island assets to Abbott for $170 million due to underutilization and significant losses affecting overall profitability [1][3][4] Group 1: Asset Sale Details - The North Island assets include the Pōkeno factory, RPD, and Jerry Green site, with an expected completion date of April 1, 2026 [3] - The Pōkeno factory, completed in 2020, has an annual capacity of 40,000 tons and is considered a state-of-the-art facility for producing various nutritional products [3] - The North Island assets are currently underperforming, with an estimated EBIT loss of NZD 20 million for the 2025 fiscal year [3][4] Group 2: Strategic Rationale - The sale is part of a strategic assessment initiated in April 2024 to address operational challenges and focus on core business areas [4][5] - By divesting these assets, Synlait aims to reduce debt, improve long-term profitability, and enhance financial stability [4][5][8] - The transaction is expected to generate additional cash flow for debt repayment and reduce interest costs, aligning with Synlait's goal to mitigate financial liquidity risks [4][5] Group 3: Financial Performance - Synlait's revenue for the 2024 fiscal year was NZD 7.439 billion, a 1.06% increase, but it reported a net loss of NZD 450 million, a 52.03% decline year-on-year [7] - The company has faced challenges such as rising commodity prices and increased financing costs, leading to a significant decline in profitability [7] - Following the asset sale, Synlait anticipates an increase in net profit of approximately NZD 10 million to NZD 15 million for the 2026 fiscal year [7][8] Group 4: Abbott's Interest - Abbott, which has been a customer of Synlait since 2020, is acquiring the North Island assets, raising speculation about its potential return to the Chinese infant formula market [2][10] - Abbott has previously exited the Chinese infant formula market due to competitive pressures and regulatory challenges, and it has not confirmed any plans to re-enter [2][10]

Core Insights - Abbott Laboratories is expected to report third-quarter earnings on October 15, 2025, with an anticipated EPS of $1.30, reflecting a 7.4% increase year-over-year, and projected revenue of $11.4 billion, up from $10.63 billion a year ago [1][6] Financial Performance - The anticipated EPS of $1.30 represents an 8.3% year-over-year growth, indicating strong performance despite a recent stock decline of 0.6%, closing at $132.57 [2] - Abbott's financial metrics include a price-to-earnings (P/E) ratio of approximately 16.36 and a price-to-sales ratio of about 5.30, suggesting a favorable market valuation [4] - The company's debt-to-equity ratio stands at 0.27, indicating a relatively low level of debt, while a current ratio of 1.82 reflects strong liquidity to cover short-term liabilities [4] Strategic Focus - Abbott's strategic emphasis on expanding its diabetes care solutions is identified as a key driver for future growth, transitioning from devices to comprehensive, data-driven care solutions [3][6] - This strategic move is expected to enhance Abbott's competitive edge and contribute to its long-term success in the healthcare industry [3] Analyst Insights - The consensus earnings estimate for Abbott has been slightly adjusted downward by 0.1% over the past month, reflecting analysts' reassessment of initial projections [5] - This adjustment could influence investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [5]

Abbott Laboratories (NYSE:ABT) will release earnings results for the third quarter, before the opening bell on Wednesday, Oct. 15.Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.30 per share, up from $1.21 per share in the year-ago period. Abbott Laboratories projects quarterly revenue of $11.4 billion, compared to $10.63 billion a year earlier, according to data from Benzinga Pro.On Sept. 19, the company's board of directors declared a quarterly common dividend ...